# DP-R212 Pharmacokinetic Study Phase I

> **NCT02814500** · PHASE1 · UNKNOWN · sponsor: **Alvogen Korea** · enrollment: 36 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** DP-R212
- **DRUG:** Amlodipine
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02814500
- **Lead sponsor:** Alvogen Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2016-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02814500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02814500, "DP-R212 Pharmacokinetic Study Phase I". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02814500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*